How to Help Your Patients Save Money on Foundayo: A Provider's Guide to Savings Programs

For healthcare providers prescribing Foundayo (orforglipron), cost counseling is now a routine part of the treatment conversation. Survey data consistently shows that out-of-pocket cost is the primary reason patients don't start or continue GLP-1 therapy. Understanding the Foundayo savings landscape — and being able to communicate it clearly to patients at the point of prescribing — can meaningfully improve treatment initiation and adherence rates.

This guide consolidates everything you and your staff need to know about Foundayo savings programs as of 2026.

The Full Foundayo Cost Picture for Patients

Foundayo pricing as of April 2026 — before any savings programs:

• 0.8 mg (starter dose): $149/month via LillyDirect self-pay
• 2.5 mg: $199/month
• 5.5 mg–17.2 mg (maintenance doses): $299/month (or $349 if refill is missed beyond 45 days for the two highest doses)

For reference, comparable injectable GLP-1s (Wegovy, Zepbound) have list prices of $1,000–$1,300/month. Foundayo's deliberate self-pay pricing strategy is meaningfully different, though still substantial for many patients.

Program 1: Foundayo Savings Card — $25/Month for Commercially Insured Patients

For commercially insured patients whose plan covers Foundayo, the Foundayo Savings Card reduces the monthly copay to as little as $25 for a 1-month, 2-month, or 3-month fill. This is Eli Lilly's primary patient affordability strategy for insured patients.

Eligibility criteria (counsel patients on these before recommending):

• Must have commercial (private/employer) drug insurance that covers Foundayo
• Cannot be enrolled in Medicare, Medicaid, TRICARE, VA, or other government-funded plans
• Must be a U.S. resident, age 18 or older with a valid prescription
• Maximum 10 fills per calendar year; card expires December 31, 2026

Important for offices to know: the savings card requires insurance coverage first. If a patient doesn't have coverage yet (PA pending, policy not updated), they cannot use the insured savings card. They can, however, use the self-pay savings card or LillyDirect self-pay pricing as a bridge.

Program 2: LillyDirect Self-Pay — The Bridge Option

For patients who are uninsured, whose insurance doesn't cover Foundayo, or who are waiting for prior authorization approval, LillyDirect self-pay pricing is the most predictable option. The costs ($149–$299/month by dose) are transparent and accessible through foundayo.lilly.com.

Key benefits of the LillyDirect bridge strategy:

• Patients can start treatment immediately rather than waiting 3–6 weeks for PA approval
• When insurance approval comes through, patients can switch to insurance + savings card ($25/month) at their next refill
• Prescription transfer from LillyDirect to a retail pharmacy (or vice versa) is straightforward
• Amazon Pharmacy, a LillyDirect partner, automatically applies eligible savings and ships to the patient's door

Program 3: Medicare — $50/Month Starting July 2026

Medicare Part D traditionally excluded coverage for weight loss drugs by federal statute. The CMS BALANCE Model, a demonstration program launching in mid-2026, changes this by enabling Medicare Part D plans to cover obesity medications including Foundayo for qualifying beneficiaries.

Eli Lilly has indicated that eligible Medicare Part D enrollees may pay approximately $50/month for Foundayo beginning July 1, 2026. For your Medicare patients:

• Coverage requires qualifying obesity-related comorbidities per BALANCE Model criteria
• Coverage is not active before July 2026 — advise Medicare patients of LillyDirect self-pay ($149–$299/month) in the interim
• Medicare patients are NOT eligible for the Foundayo Savings Card (government insurance exclusion)

The Prior Authorization Strategy: Highest Impact, Highest Yield

For commercially insured patients, the most impactful cost-reduction step is successful prior authorization — because it unlocks both coverage and the $25/month savings card. Research shows that 65–80% of GLP-1 prior authorization appeals succeed when properly documented. A proactive PA strategy includes:

• Document BMI: ≥30, or ≥27 with at least one weight-related comorbidity
• List comorbidities: Hypertension, dyslipidemia, T2DM, OSA, PCOS, cardiovascular disease, etc.
• Document prior weight management efforts: Referrals to dietitians, participation in structured weight programs, prior medication trials
• Use a Letter of Medical Necessity: Lilly provides an LOMN template at foundayo.lilly.com/hcp/savings-coverage
• Appeal denials: Over 80% of Medicare Advantage PA appeals succeed. Encourage patients not to accept first-level denials.

HSA/FSA: An Often-Overlooked Savings Tool

Advise eligible patients that HSA (Health Savings Account) and FSA (Flexible Spending Account) funds can be used for Foundayo out-of-pocket costs, including any residual cost after savings cards. Using pre-tax dollars effectively saves 20–35% of additional cost. This can be combined with the savings card for patients in the commercial insurance track.

Lilly Cares: What Prescribers Should Know

Eli Lilly's Lilly Cares patient assistance program (for low-income, uninsured patients) does not currently cover Foundayo. This is notable for providers whose patient panels include lower-income individuals. Until Foundayo is added to Lilly Cares, alternatives for these patients include:

• LillyDirect self-pay ($149/month starting dose)
• NeedyMeds.org for independent GLP-1 assistance programs
• State Medicaid programs (coverage varies and is generally more restrictive for weight loss drugs)
• Alternative GLP-1 medications that may have better assistance program coverage

A Practical Cost-Counseling Framework for Office Visits

When prescribing Foundayo, a brief cost discussion can be structured around insurance status:

• Commercial insurance (plan covers Foundayo): Apply for $25/month savings card at foundayo.lilly.com or call 1-800-545-6962. Activate before first fill.
• Commercial insurance (PA pending or plan doesn't cover it): Use LillyDirect self-pay bridge while PA is processed. Switch to savings card once approved.
• Medicare: LillyDirect self-pay now; BALANCE Model coverage expected July 2026 at ~$50/month.
• Uninsured: LillyDirect self-pay ($149–$299/month). Check NeedyMeds.org.
• Medicaid: Coverage varies by state. Check your state's Medicaid formulary or contact the plan directly.

How medfinder Supports Your Patients Beyond Cost

Even with the right savings program in place, patients can still struggle to find Foundayo at a local pharmacy. medfinder is a service that calls pharmacies on behalf of patients to locate which ones have their specific medication and dose in stock. Referring patients to medfinder alongside your cost-savings counseling ensures they have help with both the cost and the access side of the Foundayo experience.

Summary: Foundayo Savings Quick Reference for Prescribers

• Commercial insurance + coverage: $25/month (savings card, expires 12/31/2026)
• Self-pay bridge (LillyDirect): $149–$299/month by dose
• Medicare: ~$50/month expected July 2026 (BALANCE Model)
• Lilly Cares PAP: Not available for Foundayo as of 2026
• HSA/FSA: Eligible; up to 20–35% additional savings with pre-tax dollars
• Prior auth appeal success rates: 65–80% with proper documentation

Final Thoughts

Cost barriers to obesity pharmacotherapy are real and consequential — but Foundayo's launch-pricing strategy is genuinely more accessible than comparable injectables. With the right combination of prior authorization, savings card activation, and LillyDirect bridge use, many patients can access treatment at $25–$149/month. For providers looking to reduce friction in their GLP-1 prescribing workflow and help patients navigate both cost and availability, partnering with medfinder can be a valuable addition to your patient support toolkit.